For the quarter ending 2025-09-30, RNAZ has $5,226,682 in assets. $3,800,703 in debts. $2,835,916 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 2,835,916 | 7,374,815 | ||
| Grant receivable | 198,296 | 176,122 | ||
| Prepaid expenses and other current assets | 1,716,836 | 690,784 | ||
| Total current assets | 4,751,048 | 8,241,721 | ||
| Property and equipment, net of depreciation | 19,908 | 24,689 | ||
| Deferred offering costs | 455,726 | - | ||
| Total assets | 5,226,682 | 8,266,410 | ||
| Accounts payable and accrued expenses | 2,967,828 | 1,564,990 | ||
| Deferred grant income | - | 0 | ||
| Total current liabilities | 2,967,828 | 1,564,990 | ||
| Warrant liability | 832,875 | 553,714 | ||
| Long-term liabilities | 832,875 | 553,714 | ||
| Total liabilities | 3,800,703 | 2,118,704 | ||
| Common stock - 0.0001 par value, 290,000,000 shares authorized at september 30, 2025, and december 31, 2024 833,683 and 36,753 shares issued and outstanding at september 30, 2025, and december 31, 2024, respectively | 84 | 84 | ||
| Additional paid-in capital | 85,845,777 | 85,711,453 | ||
| Accumulated deficit | -84,419,882 | -79,563,831 | ||
| Total stockholders' equity (deficit) | 1,425,979 | 6,147,706 | ||
| Total liabilities and stockholders' equity (deficit) | 5,226,682 | 8,266,410 | ||
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)